Dr. Nguyen is a consultant for Ferring. Dr. Feng receives research support from Varian, and is on the advisory board for Medivation and Astellas. The remaining authors have disclosed that they have no financial interests, arrangements, affiliations, or commercial interests with the manufacturers of any products discussed in this article or their competitors.
This work is supported by the Prostate Cancer Foundation, Fitz's Cancer Warriors, David and Cynthia Chapin, Hugh Simons in Honor of Frank and Anne Simons, Scott Forbes and Gina Ventre Fund, Jeffrey Campbell in Honor of Joan Campbell, and a grant from an anonymous family foundation.
Mohler JL, Armstrong AJ, Bahnson RR et al.. NCCN Clinical Practice Guidelines in Oncology: Prostate Cancer. Verison 2.2016. Accessed March 9, 2016. To view the most recent version of these guidelines, visit NCCN.org.
Bolla M, de Reijke TM, Van Tienhoven G et al.. Duration of androgen suppression in the treatment of prostate cancer. N Engl J Med 2009;360:2516–2527.
Hanks GE, Pajak TF, Porter A et al.. Phase III trial of long-term adjuvant androgen deprivation after neoadjuvant hormonal cytoreduction and radiotherapy in locally advanced carcinoma of the prostate: the Radiation Therapy Oncology Group protocol 92-02. J Clin Oncol 2003;21:3972–3978.
- Search Google Scholar
- Export Citation
. Hanks GE Pajak TF Porter A Phase III trial of long-term adjuvant androgen deprivation after neoadjuvant hormonal cytoreduction and radiotherapy in locally advanced carcinoma of the prostate: the Radiation Therapy Oncology Group protocol 92-02. J Clin Oncol 2003; 21: 3972– 3978.
Zapatero A, Guerrero A, Maldonado X et al.. High-dose radiotherapy with short-term or long-term androgen deprivation in localised prostate cancer (DART01/05 GICOR): a randomised, controlled, phase 3 trial. Lancet Oncol 2015;16:320–327.
Muralidhar V, Regan MM, Werner L et al.. Duration of androgen deprivation therapy for high-risk prostate cancer: application of randomized trial data in a tertiary referral cancer center [published online ahead of print December 17, 2015]. Clin Genitourin Cancer, doi: 10.1016/j.clgc.2015.12.008.
- Search Google Scholar
- Export Citation
. Muralidhar V Regan MM Werner L Duration of androgen deprivation therapy for high-risk prostate cancer: application of randomized trial data in a tertiary referral cancer center [published online ahead of print December 17, 2015]. Clin Genitourin Cancer, doi: 10.1016/j.clgc.2015.12.008.
Nguyen PL, Alibhai SM, Basaria S et al.. Adverse effects of androgen deprivation therapy and strategies to mitigate them. Eur Urol 2015;67:825–836.
Nanda A, Chen MH, Braccioforte MH et al.. Hormonal therapy use for prostate cancer and mortality in men with coronary artery disease-induced congestive heart failure or myocardial infarction. JAMA 2009;302:866–873.
Ziehr DR, Chen MH, Zhang D et al.. Association of androgen-deprivation therapy with excess cardiac-specific mortality in men with prostate cancer. BJU Int 2015;116:358–365.
Nguyen PL, Je Y, Schutz FA et al.. Association of androgen deprivation therapy with cardiovascular death in patients with prostate cancer: a meta-analysis of randomized trials. JAMA 2011;306:2359–2366.
D'Amico AV, Chen MH, Renshaw AA et al.. Androgen suppression and radiation vs radiation alone for prostate cancer: a randomized trial. JAMA 2008;299:289–295.
Greene DE, Mayadev JS, Valicenti RK. Radiation treatment for patients with intermediate-risk prostate cancer. Ther Adv Urol 2012;4:113–124.
Overview of the SEER Program. National Cancer Institute; Surveillance, Epidemiology, and End Results Program Web site. Available at: http://seer.cancer.gov/about/overview.html. Accessed September 3, 2015.
Warren JL, Klabunde CN, Schrag D et al.. Overview of the SEER-Medicare data: content, research applications, and generalizability to the United States elderly population. Med Care 2002;40(8 Suppl):IV-3-18.
Shahinian VB, Kuo YF, Freeman JL, Goodwin JS. Risk of fracture after androgen deprivation for prostate cancer. N Engl J Med 2005;352:154–164.
Keating NL, O'Malley AJ, Smith MR. Diabetes and cardiovascular disease during androgen deprivation therapy for prostate cancer. J Clin Oncol 2006;24:4448–4456.
Schmid M, Hanske J, Ravi P et al.. Relationship between androgen deprivation therapy and community-acquired respiratory infections in patients with prostate cancer [published online ahead of print January 13, 2016]. Int J Urol, doi: 10.1111/iju.13043.
Schmid M, Sammon JD, Reznor G et al.. Dose-dependent effect of androgen deprivation therapy for localized prostate cancer on adverse cardiac events [published online ahead of print June 13, 2015]. BJU Int, doi: 10.1111/bju.
Klabunde CN, Potosky AL, Legler JM, Warren JL. Development of a comorbidity index using physician claims data. J Clin Epidemiol 2000;53:1258–1267.
Zumsteg ZS, Spratt DE, Pei I et al.. A new risk classification system for therapeutic decision making with intermediate-risk prostate cancer patients undergoing dose-escalated external-beam radiation therapy. Eur Oncol 2013;64:895–902.
Muralidhar V, Chen MH, Reznor G et al.. Definition and validation of “favorable high-risk prostate cancer”: implications for personalizing treatment of radiation-managed patients. Int J Radiat Oncol Biol Phys 2015;93:828–835.
PSA Values and SEER Data. National Cancer Institute: Surveillance, Epidemiology, and End Results Program. Available at: http://seer.cancer.gov/data/psa-values.html. Accessed September 3, 2015.
Schymura MJ, Sun L, Percy-Laurry A. Prostate cancer collaborative stage data items--their definitions, quality, usage, and clinical implications: a review of SEER data for 2004-2010. Cancer 2014;120(Suppl 23):3758–3770.
Efstathiou JA, Bae K, Shipley WU et al.. Cardiovascular mortality and duration of androgen deprivation for locally advanced prostate cancer: analysis of RTOG 92-02. Eur Urol 2008;54:816–823.
Alibhai SM, Duong-Hua M, Sutradhar R et al.. Impact of androgen deprivation therapy on cardiovascular disease and diabetes. J Clin Oncol 2009;27:3452–3458.
Ziehr DR, Mahal BA, Aizer AA et al.. Income inequality and treatment of African American men with high-risk prostate cancer. Urol Oncol 2015;33:18 e7–3.
Mahal BA, Aizer AA, Ziehr DR et al.. Trends in disparate treatment of African American men with localized prostate cancer across National Comprehensive Cancer Network risk groups. Urology 2014;84:386–392.
Mahal BA, Ziehr DR, Aizer AA et al.. Getting back to equal: the influence of insurance status on racial disparities in the treatment of African American men with high-risk prostate cancer. Urol Oncol 2014;32:1285–1291.